Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L04-002
- Development stage
- Unknown
- Lead developer
- Abbio
- Modality
- Small Molecules
01
Overview
L04-002 is a small molecule immunosuppressant being developed by Abbio Therapeutics for the treatment of multiple sclerosis. The candidate is currently in the registration (pre-launch) phase. It is designed to modulate immune responses associated with the pathogenesis of multiple sclerosis, aiming to reduce neuroinflammation and prevent demyelination in the central nervous system.
Beyond the preview
Go deeper on L04-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L04-002.